Pressure BioSciences (OTCQB: PBIO) is playing a major role in the war on cancer. Three out of its first five next-generation PCT-based instrument systems have been snapped up by the ProCan lab at the Children’s Medical Research Institute in Australia. U.S. Vice President Joe Biden recently named the ProCan facilities an official collaborator in the United States’ initiative – known as Cancer Moonshot (CM) – to accelerate the development of combination immunotherapies in cancer treatment. The CM program arose after Biden, whose son succumbed to the disease in 2015, promised a “moonshot” to attack cancer. The CM program has garnered widespread bipartisan support, and, earlier this month, the 21st Century Cures Act, which provides $1.8 billion in funding for the program, was signed into law. ProCan will use Pressure BioSciences’ Barococycler to prepare the 70,000-plus tumor samples it plans to analyze. This high-profile employment of the Barococycler is expected to boost the company’s revenues, which are already climbing. As of September 30, 2016, Pressure Biosciences posted three quarters of half million-dollar revenue.
To learn more visit www.pressurebiosciences.com
About Pressure BioSciences, Inc. (PBI)
Pressure BioSciences, Inc. develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. Its products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. To date, PBI has installed over 260 PCT systems in approximately 160 sites worldwide. There are over 100 publications citing the advantages of the PCT platform over competitive methods, many from key opinion leaders. PBI’s primary application development and sales efforts are in the biomarker discovery and forensics areas. Customers also use its products in other areas, such as drug discovery & design, bio-therapeutics characterization, soil & plant biology, vaccine development, histology, and forensic applications.
About NetworkNewsBreak
NetworkNewsBreak (NNB) provides a rapid summary of corporate news that caught the attention of NetworkNewsWire (NNW). NNB keeps you up-to-date on active US Public Companies complementary to NNW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW is uniquely positioned to best serve private and public companies who need to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information, visit https://www.networknewswire.com.
Please see full disclaimers on the NetworkNewsWire website: http://nnw.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
